↓ Skip to main content

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Overview of attention for article published in BMC Cancer, September 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
5 Mendeley